J&J’s Veridex To Lead Development Of Next-Gen Cancer Diagnostic
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson subsidiary Veridex will partner with Massachusetts General Hospital to help bring a next-generation cancer blood test to market, both institutions announced Jan. 3.
You may also be interested in...
J&J Highlights Late-Stage R&D Prospects Across Pharma Division
J&J says its success at integrating external and internal innovation, focus on understanding causes of disease and commercial excellence have helped its pharma subsidiary weather a $9 billion patent cliff and recoup growth prospects. One observation from its May 23 analyst meeting: seemingly more than most companies, Janssen systemically incorporates biomarkers and companion diagnostics beyond oncology into all of its core development programs.
Study Shows Circulating Tumor Cell Chips Track Cancer Drug Response
Circulating tumor cell chips show promise as monitors of cancer therapy response in a study led by the Massachusetts General Hospital Cancer Center published July 2 in the New England Journal of Medicine
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.